Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 6

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 6
---
 have direct access to management, and have discretion to hire independent advisors at the Company’s expense.

Sustainability Highlights

Our Board has a long-standing commitment to corporate responsibility.

We are committed to remaining cognizant of our impact on the wider environment in which we operate including Company initiatives designed to improve manufacturing yields and measuring baseline emissions to identify opportunities reduce waste.

We are committed to providing equal opportunity in all aspects of employment.

Our Board believes that gender, racial and ethnic diversity are important in providing diverse viewpoints. Our commitment to that belief is reflected in the composition of our Board, which includes three women among its five most recent additions.

Investor Engagement in 2024

Throughout 2024, including following our 2024 annual meeting, our leadership team consistently engaged with our top 25 shareholders representing approximately 68% of our outstanding common stock to discuss the progress of our clinical trials, our business strategy, our financial performance and strategic initiatives and our corporate guidance. We also provided stockholders an overview of the overall state of the gene therapy industry.

<div align='center'>5</div>

PROP OSAL 1: ELECTION OF DIRECTORS Under our Restated Certificate of Incorporation (the “Certificate of Incorporation”) and Amended and Restated Bylaws ("the Bylaws"), the Board is divided into three classes of roughly equal size. The members of each class are elected to serve a three-year term with the term of office of each of the three classes ending in successive years. Pursuant to our Bylaws, the Board has fixed the current number of directors at ten. Allan Fox, Alexandra Glucksmann, Ph.D., Curran Simpson and Jennifer Zachary, are the four Class I directors whose terms expire at this Annual Meeting. The Board has nominated Messrs. Fox and Simpson, Dr. Glucksmann and Ms. Zachary (collectively, the “nominees” and each, a “nominee”) to serve until the 2028 annual meeting of stockholders or until their successors are duly elected and qualified, or until their earlier death, resignation, retirement, disqualification or other removal. Each of the nominees was recommended for election by the Nominating and Corporate Governance Committee, and each such recommendation was approved unanimously by the Board. Shares represented by signed proxy cards will be voted on Proposal 1 “For” the election of the nominees to the Board at the Annual Meeting, unless otherwise marked on the card. If any of the nominees becomes unavailable for election as a result of an unexpected occurrence